Is it time to replace vancomycin in the treatment of methicillin-resistant staphylococcus aureus infections?

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1779-1788

  Van Hal, Sebastiaan J ^a,b   Fowler, Vance G ^c,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

AUC MIC targets; minimum inhibitory concentration (MIC); MRSA, hVISA, VISA; Staphylococcus aureus; vancomycin

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL PRACTICE; DRUG COST; DRUG TREATMENT FAILURE; HUMAN; INFECTION CONTROL; KIDNEY FAILURE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS;

AUC/MIC TARGETS; MINIMUM INHIBITORY CONCENTRATION (MIC); MRSA, HVISA, VISA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84878297844     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit178     Document Type: Article

References (71)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methi-cillin-resistant Staphylococcus aureus clinical strain with reduced van-comycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
2. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3.
3. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
4. Tenover FC, Moellering RC, Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
5. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543-8.
6. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-42.
7. Sakoulas G, Moellering RC, Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46(suppl 5): S360-7.
8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
9. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
10. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vanco-mycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71.
11. Chen SY, Liao CH, Wang JL, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis 2012; 55:1329-37.
12. Rojas L, Bunsow E, Munoz P, Cercenado E, Rodriguez-Creixems M, Bouza E. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients. J Antimicrob Chemother 2012; 67:1760-8.
13. Wi YM, Kim JM, Joo EJ, et al. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2012; 40:108-13.
14. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2012; 56:5164-70.
15. Yeh YC, Yeh KM, Lin TY, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect 2012; 45:214-20.
16. Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 2012; 17:1329-36.
17. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heterore-sistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47:1640-4.
18. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011; 49:1489-94.
19. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55:405-10.
20. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42(suppl 1): S13-24.
21. Adam HJ, DeCorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69:307-13.
22. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat Rev Microbiol 2004; 2:289-300.
23. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharma-cokinet 2004; 43:925-42.
24. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969-74.
25. van Hal SJ, Barbagiannakos T, Jones M, et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66:2284-7.
26. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013; 57:1654-63.
27. Bland CM, Porr WH, Davis KA, Mansell KB. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest(R) and an automated testing method. South Med J 2010; 103:1124-8.
28. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37:95-101.
29. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734-44.
30. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
31. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
32. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-7.
33. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6.
34. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51-8.
35. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methi-cillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
36. Wolff M, Mourvillier B. Linezolid for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2012; 55:160-1.
37. Lahey T. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis 2012; 55:159-60.
38. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, 2nd. Methi-cillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67:1267-70.
39. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of cef-taroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013; 19:42-9.
40. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80.
41. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012; 25:362-86.
42. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacter-aemia. J Antimicrob Chemother 2011; 66:2386-92.
43. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
44. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
45. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 2011; 6:e21217.
46. Cameron DR, Howden BP, Peleg AY. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis 2011; 53:576-82.
47. Cameron DR, Ward DV, Kostoulias X, et al. Serine/threonine phospha-tase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis 2012; 205:1677-87.
48. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009; 53:3447-52.
49. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from north east Scotland from 2006 to 2010. J Clin Microbiol 2012; 50:318-25.
50. Gasch O, Ayats J, Angeles Dominguez M, et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 2011; 90:319-27.
51. Talbot GH, Bradley J, Edwards JE, Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68.
52. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260-4.
53. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013, 68:4-11.
54. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9:617-24.
55. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bac-teraemia in a daptomycin-naive patient: a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603-10.
56. Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27:433-7.
57. Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy 2013; 33:3-10.
58. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6.
59. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006; 57:506-10.
60. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-94.
61. Alos JI, Garcia-Canas A, Garcia-Hierro P, Rodriguez-Salvanes F. Van-comycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008; 62:773-5.
62. Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008; 52:757-60.
63. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46:2950-4.
64. Sader HS, Fey PD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009; 53: 4127-32.
65. Ho PL, Lo PY, Chow KH, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 2010; 60:140-5.
66. Adam HJ, Louie L, Watt C, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents Chemother 2010; 54: 945-9.
67. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Vancomy-cin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J Clin Microbiol 2011; 49:269-74.
68. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
69. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
70. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemo-ther 2012; 56: 634-8.
71. Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical, microbio-logic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2010; 67:228-33.